drugset
drugset / Trial / NCT03726814

A Clinical Study of iEPC Intervent Subjects With Cerebral Hemorrhagic Stroke

NCT03726814 ↗

Phase 0 Unknown 12 enrolled Allife Medical Science and Technology Co., Ltd.
SequentialOpen-labelTreatment

Summary

This is a single centre、single arm、open-label，to investigate the safety and efficacy of EPC transplantation in the brain

Timeline

Start
2018-12
Primary completion
2018-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject EPC Cell therapy — Other

Indications

ischemic stroke